Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC
Clinical trial NCT05987826 · UNKNOWN
Trial details
- NCT number
- NCT05987826
- Sponsor
- Shanghai Zhongshan Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-01
- Primary completion
- 2024-08-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.